The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Orchestra Biomed Holdings Inc is $10.00, about 135.8% above its August 7 closing price of $4.24
OBIO•
